.jpg?cb=5814680665433cc71e4f5bd2d8112904)
Novo Holdings will acquire an approximately 60% controlling stake in Singe Use Support, alongside the two company founders who will each retain 10% and Danaher which will retain 20% of the share capital.
Related Posts
UK MHRA’s new International Recognition Procedure Goes Live
From 1 January 2024, developers of new medicines can now submit applications via the MHRA’s new, International Recognition Procedure (IRP). The…
Amneal Receives FDA Approval for Parkinson’s Treatment
Amneal Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its CREXONT extended-release capsules for Parkinson’s…
.jpg?cb=7f6902545549cd6a6a653a7f6624a250&w=740)
Working together for a sustainable future
Bürkert Fluid Control Systems has taken a stake in Green Elephant Biotech as a strategic investor so the two companies…